Certified Diabetes Educator Practice Exam 2026 - Free Practice Questions and Study Resource.

Canagliflozin is associated with an increased risk of amputation, particularly of the lower extremities. This association stems from clinical trial data that indicated a higher incidence of amputations in patients treated with canagliflozin compared to those on a placebo. The mechanism behind this increased risk may relate to factors such as dehydration, urinary tract infections, and diabetic foot issues, which are more pronounced in individuals with diabetes.

This risk led to a careful consideration of the benefits versus risks when prescribing canagliflozin, making it critical for healthcare providers to monitor their patients closely and manage risk factors effectively. The other SGLT2 inhibitors mentioned do not have the same level of evidence linking them to amputations, emphasizing the unique profile of canagliflozin in this regard.